Non-Proliferative Diabetic Retinopathy Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Non-Proliferative Diabetic Retinopathy Market is segmented By Type (Mild NPDR, Moderate NPDR, Severe NPDR), By Treatment (Anti-Vascular Endothelial Growth Factor (VFGF) Medication, Intraocular Steroid Injection (Triamcinolone Acetonide (TA)), Steroid Implants, Vitrectomy), By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.

Report Overview

The Global Non-Proliferative Diabetic Retinopathy Market reached US$ 2.68 billion in 2023 and is expected to reach US$ 4.71 billion by 2031 growing with a CAGR of 7.3% during the forecast period 2024-2031.

Non-proliferative diabetic retinopathy (NPDR) is a prevalent eye condition that arises as a complication of diabetes mellitus. It is marked by damage to the retinal blood vessels caused by prolonged elevated blood sugar levels. In its early stages, NPDR is often asymptomatic, but if left unmonitored and untreated, it can result in vision impairment. NPDR is categorized into mild, moderate, and severe stages, with potential symptoms including blurred vision, floaters, and challenges with night vision.

 Mild NPDR is defined by the presence of microaneurysms, with no notable impact on vision, moderate NPDR this stage features more pronounced changes in the retina, such as retinal hemorrhages and exudates, which may start to influence vision, and severe NPDR is characterized by a substantial number of retinal hemorrhages and an increased risk of progressing to proliferative diabetic retinopathy (PDR), where abnormal new blood vessels develop in the retina.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising prevalence of diabetes and diabetes-related blindness

The demand for the global non-proliferative diabetic retinopathy market is driven by multiple factors. One of the primary factors is the rising prevalence of diabetes and diabetes-related blindness

 According to an NCBI research publication in February 2023, diabetic retinopathy is one of the primary causes of vision loss worldwide and has become more prevalent in various parts of the globe over the past 30 years. This condition results from elevated blood sugar levels that harm the blood vessels in the retina, resulting in vision issues and potentially leading to blindness. 

As per CDC estimates in 2021, an estimated 9.6 million individuals in the United States were diagnosed with diabetic retinopathy (DR), which includes 1.84 million people experiencing vision-threatening forms of the disease. Among those with diabetes, the prevalence of DR was lowest at 13.0% for individuals under 25 years old and highest at 28.4% for those aged 65 to 79. Additionally, there were 8.94 million people aged 40 and older living with DR, with 1.71 million of them having vision-threatening DR. The global prevalence of diabetes was estimated at 463 million individuals, and this number is expected to rise to 700 million by 2045.

Moreover, government initiatives and major players in the industry more focus on clinical trials &  getting positive results that would drive this market growth. For instance, in June 2024, the lowering events in non-proliferative retinopathy in Scotland (LENS) Trial, conducted by Oxford Population Health revealed that fenofibrate, a commonly used cholesterol-lowering medication, substantially reduces the progression of early diabetic retinopathy, a vision-threatening complication of diabetes. This is the first large-scale study specifically designed to evaluate the impact of fenofibrate on eye outcomes in patients with early-stage diabetic retinopathy.

Also, in November 2023, Kodiak Sciences Inc. announced that it would present data on tarcocimab tedromer at the upcoming annual meeting of the American Academy of Ophthalmology (AAO). During the Retina Subspecialty Day, the detailed findings from the Phase 3 GLOW study, which evaluates tarcocimab tedromer in patients with non-proliferative diabetic retinopathy, will be shared for the first time.

Restraints

Factors such as adverse effects associated with the drugs, high cost of treatment, limited reimbursement policies, limited awareness, and are expected to hamper the market.

Market Segment Analysis

The global non-proliferative diabetic retinopathy market is segmented based on type, treatment, end-user, and region.

The anti-vascular endothelial growth factor (VFGF) medication segment accounted for approximately 68.6% of the global non-proliferative diabetic retinopathy market share

The anti-vascular endothelial growth factor (VFGF) Medication segment is expected to hold the largest market share over the forecast period. Anti-VEGF medications are very effective in treating diabetic retinopathy, especially in situations where there is abnormal growth of blood vessels. These medications function by blocking the vascular endothelial growth factor (VEGF), which plays a key role in the development of new blood vessels, they help lower the risk of vision loss related to diabetic retinopathy.

The presence of widely recognized anti-VEGF drugs, such as Eylea, Avastin, Lucentis, and Macugen, contributes significantly to the growth of the anti-VEGF segment in the diabetic retinopathy market. These medications have received approval from the U.S. FDA and are extensively used in clinical settings, which is driving this market growth.

Ongoing progress in research and development is expected to improve the effectiveness of anti-VEGF therapies for diabetic retinopathy. Pharmaceutical companies are actively engaged in enhancing these drugs and investigating new formulations, which may lead to expanded applications in the treatment of this condition. These advancements could potentially offer more effective and targeted solutions for managing diabetic retinopathy.

Moreover, major players in the industry more focus on the treatments for non-proliferative diabetic retinopathy and a rising number of clinical trials drive this segment growth. For instance, in July 2024, Ocuphire Pharma is set to showcase its lead oral candidate, APX3330, for diabetic retinopathy (DR) at two significant scientific meetings. The company, which focuses on developing therapies for retinal and refractive eye disorders, aims to highlight the potential of APX3330, an oral small-molecule inhibitor of Ref-1 (reduction-oxidation effector factor-1 protein), specifically for the treatment of non-proliferative diabetic retinopathy (NPDR).

Similarly, in May 2024, EyePoint Pharmaceuticals, Inc. announced the topline results from its Phase 2 PAVIA clinical trial assessing DURAVYU (vorolanib intravitreal insert), formerly known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The results indicate that DURAVYU has a biological effect on NPDR patients and demonstrates a favorable safety and tolerability profile. However, the trial did not achieve its pre-defined primary endpoint. The company plans to review the complete 12-month data to determine the next steps for DURAVYU as a potential NPDR treatment.

In addition, government initiatives on anti-vascular endothelial growth factor (VFGF) would propel this segment's growth in this region. For instance, in  February 2023, a recent National Institutes of Health-supported clinical trial found that early treatment of diabetes-related eye disease with anti-VEGF drugs slowed progression to severe disease, but did not improve visual acuity compared to treating more severe disease once it developed. The recommendation to monitor patients regularly for vision-threatening complications of diabetes and to treat only as needed stems from findings indicating that early intervention with anti-VEGF treatments does not necessarily enhance visual acuity.

Market Geographical Analysis

North America accounted for approximately 44.7% of the global non-proliferative diabetic retinopathy market share

North America region is expected to hold the largest market share over the forecast period. Diabetic retinopathy (DR) is a prevalent eye complication associated with diabetes. If it's not treated can worsen and lead to severe vision-threatening issues, including diabetic macular edema and proliferative diabetic retinopathy. Among the 36 million American adults diagnosed with diabetes, it is estimated that 10 million are affected by diabetic retinopathy.

In this region, the increasing aging population, favorable reimbursement policies, and well-advanced healthcare infrastructure help to drive this market growth. Moreover, a major number of key players presence in this region, product launches & approvals would drive this market growth. For instance, in May 2024, Biocon Biologics Ltd (BBL) announced that the U.S. Food and Drug Administration (FDA) had approved its first-to-file Treatment for Yesafili, an interchangeable biosimilar of aflibercept. 

Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is intended for treating various ophthalmic conditions and is a biosimilar to the reference product EYLEA (aflibercept). This approval allows Biocon to enter the U.S. ophthalmology market, expanding its therapeutic offerings.

Also, in August 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). The recommended dosing for EYLEA HD is 8 mg (0.07 mL of a 114.3 mg/mL solution) administered every four weeks for the first three months across all indications, followed by 8 mg every 8 to 16 weeks (2 to 4 months) for wAMD and DME, and every 8 to 12 weeks (2 to 3 months) for DR.

Market Segmentation

By Type

• Mild NPDR
• Moderate NPDR
• Severe NPDR

By Treatment 

• Anti-Vascular Endothelial Growth Factor (VFGF) Medication
  • Avastin
  • Eylea
  •  Lucentis
• Intraocular Steroid Injection (Triamcinolone Acetonide (TA))
•  Steroid Implants
  • Dexamethasone Intravitreal Implant 
  • Fluocinolone Acetonide Intravitreal Implant
•  Laser Surgery (Photocoagulation)
• Vitrectomy

 By End User 

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Market Competitive Landscape

The major global players in the non-proliferative diabetic retinopathy market include Bayer AG, Regeneron Pharmaceuticals Inc., Biocon, F. Hoffmann-La Roche, AbbVie Inc., Novartis AG, Oxurion NV, Ampio Pharmaceuticals, Inc., Glycadia Pharmaceuticals and Ocuphire Pharma, Inc. among others.

Key Developments

• In June 2024, Ocuphire Pharma, Inc. announced that updates on its leading candidate, APX3330, for diabetic retinopathy (DR), will be presented at the Clinical Trials at the Summit meeting in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit in Boston.
• In February 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection for treating preterm infants with retinopathy of prematurity (ROP). This marks the first pediatric approval for EYLEA, which is now indicated to treat five retinal diseases caused by abnormal blood vessel growth in the eye (ocular angiogenesis).

 Why Purchase the Report?

• To visualize the global non-proliferative diabetic retinopathy market segmentation based on type, treatment, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of the non-proliferative diabetic retinopathy market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The global non-proliferative diabetic retinopathy market report would provide approximately 62 tables, 59 figures, and 183 pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies